These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 20385331)

  • 1. [Oral therapy for multiple sclerosis!].
    de Seze J
    Rev Neurol (Paris); 2010 Apr; 166(4):363-4. PubMed ID: 20385331
    [No Abstract]   [Full Text] [Related]  

  • 2. Behind the paper: saved from the drain.
    Dolgin E
    Nat Med; 2010 Apr; 16(4):378. PubMed ID: 20376044
    [No Abstract]   [Full Text] [Related]  

  • 3. Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis.
    Nadjar Y; Coutelas E; Prouteau P; Panzer F; Paquet D; Saint-Val C; Créange A
    Clin Neurol Neurosurg; 2011 May; 113(4):316-22. PubMed ID: 21269761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis.
    Giuliani F; Fu SA; Metz LM; Yong VW
    J Neuroimmunol; 2005 Aug; 165(1-2):83-91. PubMed ID: 15958276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy of multiple sclerosis: the PROOF trial.
    Boster A; Racke MK
    Expert Opin Pharmacother; 2009 Jun; 10(8):1235-7. PubMed ID: 19463066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H; Hohlfeld R
    Neurology; 2009 Mar; 72(11):1008-15. PubMed ID: 19289741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
    Elovaara I; Atula S; Erälinna JP; Färkkilä M; Pirttilä T; Remes A; Ruutiainen J; Varis T; ;
    Duodecim; 2010; 126(2):199-200. PubMed ID: 20405605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for multiple sclerosis: the curious case of interferon beta.
    Stüve O; Ransohoff RM
    Arch Neurol; 2009 Oct; 66(10):1193-4. PubMed ID: 19822773
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
    Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B
    Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of interferon-beta treatment on the blood-brain barrier.
    Kraus J; Oschmann P
    Drug Discov Today; 2006 Aug; 11(15-16):755-62. PubMed ID: 16846804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
    Ouallet JC
    Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosis improves through early therapy from the beginning!].
    Med Monatsschr Pharm; 2007 Oct; 30(10):381-2. PubMed ID: 17966289
    [No Abstract]   [Full Text] [Related]  

  • 15. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
    Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
    Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of methotrexate use in a patient with rheumatoid arthritis and multiple sclerosis.
    Li S; Kaur PP; Berney SN
    J Clin Rheumatol; 2008 Aug; 14(4):241-2. PubMed ID: 18766127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
    Parry A; Corkill R; Blamire AM; Palace J; Narayanan S; Arnold D; Styles P; Matthews PM
    J Neurol; 2003 Feb; 250(2):171-8. PubMed ID: 12574947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al].
    Labetouelle M
    J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant human interferon.
    Weiss RC
    Vet Rec; 1990 Feb; 126(7):176-7. PubMed ID: 2155502
    [No Abstract]   [Full Text] [Related]  

  • 20. A multicenter study of recombinant interferon-alpha 2b in the treatment of multibacillary leprosy.
    Ganapati R; Pai VV; Banerji U; Thomas J; Saha B
    Int J Lepr Other Mycobact Dis; 1997 Dec; 65(4):495-7. PubMed ID: 9465161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.